ArticleDermatology and therapy2026
Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis-A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control.
methodsThis multicenter retrospective analysis of prospectively collected LANDSCAPE registry data included patients with moderate-to-severe AD receiving stable upadacitinib 15 mg or 30 mg once daily. Patients who underwent dose modification from 15 to 30 mg or from 30 to 15 mg during the 52-week observation period were excluded from the present analysis to ensure that longitudinal outcomes and cumulative disease-control estimates could be consistently attributed to a stable upadacitinib dose. Outcomes were assessed at baseline and weeks 16, 32, and 52. Moderate disease control was defined as EASI75 plus peak pruritus numerical rating scale (pp-NRS) ≤ 4, and optimal disease control/minimal disease activity (MDA) as EASI90 plus pp-NRS ≤ 1. Cumulative control was estimated as equivalent days in target using a time-in-target approach.
resultsOverall, 433 patients were included; 315 (72.7%) received 15 mg and 118 (27.3%) received 30 mg. At week 52, EASI75 and EASI90 were achieved by 85.7% and 72.7% of patients, respectively; moderate and optimal disease control/MDA were achieved by 80.6% and 62.6%. Patients spent a mean of 253.3 ± 101.9 equivalent days in moderate disease control and 176.1 ± 124.4 days in optimal control/MDA. Sustained moderate and optimal disease control from weeks 16 to 52 were achieved by 63.0% and 38.3%, respectively. Overall, 27.0% experienced at least one adverse event, with no permanent treatment discontinuations due to adverse events.
conclusionUpadacitinib provided sustained real-world disease control over 52 weeks. Time-in-target measures may complement conventional endpoints by better reflecting persistence of therapeutic benefit.
Indexed as
Identifiers
42879117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.